pharma · Kidney Dysfunction · Obesity
LianBio
Jian Li
Jian Li is a pharma organization headquartered in CN. Primary therapeutic focus areas include Kidney Dysfunction, Obesity, Fibrosis, Ebola Virus Disease, Bladder Cancer. NovaPharmaNews links 28 clinical program(s), 0 dru
CN HQ
2019 Founded
47 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2019
- Employees
- 47
- Programs
- 28
- Drugs
- 40
- Patents
- 0
Part1:Recombinant two-component COVID-19 vaccine (CHO cell)
Phase 2 · mab · COVID-19
Part1:Recombinant two-component COVID-19 vaccine (CHO cell) for COVID-19 is a Phase 2 program (mab) at Jian Li with 1 ClinicalTrials.gov record(s).
Internal code REC611C301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Jian Li
- Phase
- Phase 2
- Modality
- mab
- Indication
- COVID-19
- Status
- completed
- Trials
- 1